Skip to content

Definium Therapeutics

US · DFTX #2132 by market cap Listed 1970
28.34 -1.14 -3.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 4.54 Expensive vs history 70th percentile
5-year average 3.99 · #374 of 514 in Biotechnology
P/E ratio -10.99 Cheap vs history 9th percentile
5-year average -4.24 · forward -15.79
P/S ratio --
5-year average 0.00 · forward 276.67

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Definium Therapeutics (DFTX) 3.88B -9.71 4.01 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value37.00 Economic moatNone UncertaintyVery High

Trading 30.6% below Morningstar's fair value estimate.

Fair value

Definium Therapeutics Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 13% discount to our quantitative fair value estimate of $37.00 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 4.1 lies in the bottom 40% compared with global peers. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

Conversely, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, sits in the top 30% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Definium Therapeutics discussion 0 comments

Add a comment